Current Trends,30- or 31-amino-acid-long peptide hormone

The liraglutide peptide length is a critical characteristic that defines its structure and function as a therapeutic agent. As a lipopeptide and an analogue of human glucagon-like peptide-1 (GLP-1), liraglutide is engineered for enhanced stability and prolonged action. Understanding the precise peptide composition and its length is fundamental to comprehending its mechanism of action, efficacy in treating conditions like type 2 diabetes and obesity, and its overall pharmacokinetic profile.

Liraglutide is fundamentally a modified peptide derived from the naturally occurring hormone GLP-1. Human GLP-1, in its active form, is a 30- or 31-amino-acid-long peptide hormone. Liraglutide's structure is based on the GLP-1 (7-37) sequence, but with specific modifications. The liraglutide peptide length is typically cited as 31 amino acids. This is a key difference from the native GLP-1, which undergoes enzymatic cleavage to produce its active forms.

One of the significant modifications that contributes to liraglutide's prolonged activity is the attachment of a fatty acid chain (a hexadecanoyl group) to a lysine residue. This acylation transforms liraglutide into a long-acting, fatty acylated glucagon-like peptide-1. This structural alteration significantly impacts its interaction with plasma proteins and its resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). The size of the liraglutide peptide molecule, including the attached fatty acid, contributes to its reduced renal clearance and extended half-life, allowing for once-daily administration. The molecular weight of liraglutide is approximately 3751.29 Daltons, with a molecular formula of C172H265N43O51.

The fact that liraglutide is a long-acting GLP-1 receptor agonist is directly attributable to its engineered peptide structure and the resulting prolonged presence in the body. Unlike native GLP-1, which has a very short half-life of only a few minutes, liraglutide's half-life after subcutaneous injection in humans is approximately 10-14 hours. This extended duration of action is crucial for its therapeutic benefits. The amino acid sequence of liraglutide is nearly identical to endogenous human GLP-1, with only a single amino acid substitution. This similarity ensures potent binding to the GLP-1 receptor, activating downstream signaling pathways that enhance insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite.

The development of liraglutide represents a significant advancement in the field of peptide therapeutics. The careful design of its peptide structure, including its specific length and the addition of the fatty acid moiety, has resulted in a drug that offers improved glycemic control and aids in weight management for individuals with type 2 diabetes and obesity. Researchers continue to explore the nuances of peptide design and synthesis, including methods for producing high-purity liraglutide API and investigating the liraglutide and semaglutide difference in their structural and pharmacokinetic properties. The precise liraglutide peptide length is not just a number but a fundamental determinant of its sophisticated pharmacological profile.